A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 1, 2010, Pages 150-159

  Hunfeld, N G ^a   Touw, D J ^a   Mathot, R A ^b   Mulder, P G H ^b   Van Schaik, R H ^b   Kuipers, E J ^b   Kooiman, J C ^a   Geus, W P ^a  

^a HAGA HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; ESOMEPRAZOLE; PANTOPRAZOLE;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; PH; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MONITORING, PHYSIOLOGIC; OMEPRAZOLE; POLYMORPHISM, GENETIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71449111039     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04150.x     Document Type: Article

References (40)

1. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992 51 (Suppl. 1 59 67.
2. Howden CW, Burget DW, Hunt RH. Appropriate acid suppression for optimal healing of duodenal ulcer and gastro-oesophageal reflux disease. Scand J Gastroenterol 1994 201 (Suppl. 79 82.
3. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007 41 (6 Suppl 2 S226 42.
4. Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 14 : 861 867.
5. Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002 47 : 954 958.
6. Geus WP, Mathôt RAA, Mulder PGH, Lamers CBHW. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther 2000 14 : 1057 1064.
7. Hunfeld NG, Mathot RA, Touw DJ, et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 2008 65 : 752 760.
8. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990 12 : 415 416.
9. Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001 15 : 1929 1937. (Pubitemid 34014349)
10. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001 40 : 411 426. (Pubitemid 32656078)
11. Schwab M, Klotz U, Hofmann U, et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005 78 : 627 634.
12. Tanaka M, Ohkubo T, Otani K, et al. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin Pharmacol Ther 2001 69 : 108 113.
13. Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006 24 : 377 385.
14. th 2009.
15. Geus WP, Mulder PG, Nicolai JJ, Van den Boomgaard DM, Lamers CB. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Pharmacol Ther 1998 12 : 329 335.
16. Merki HS, Witzel L, Walt RP, et al. Day-to-day variation of 24-hour intragastric acidity. Gastroenterology 1988 94 : 887 891.
17. Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. J Chromatogr 1984 309 : 347 356.
18. Boeckmann AJ, Sheiner LB, Beal SL. Nonmem User Guide-Part III. San Francisco : University of California, 1999.
19. Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995 36 : 12 6.
20. Jhala NC, McFarland MM, Brightman SA, Morale B, Rubin W, Atkinson BF. The effects short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. Am J Gastroenterol 1995 90 : 1824 1828.
21. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004 60 : 531 539. (Pubitemid 39517904)
22. Miner P Jr., Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 98 : 2616 2620.
23. Wilder-Smith CH, Röhss K, Bondarov P, Hallerbäck B, Svedberg LE, Ahlbom H. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. Aliment Pharmacol Ther 2004 20 : 1099 1104.
24. Hassan-Alin M, Andersson T, Bredberg E, Röhss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000 56 : 665 670.
25. Hassan-Alin M, Andersson T, Niazi M, Röhss K. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 2005 60 : 779 784.
26. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994 37 : 597 604.
27. Abelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000 28 : 966 972. (Pubitemid 30612617)
28. Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997 62 : 619 628.
29. Baldwin RM, Ohlsson S, Pedersen RS, et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 2008 65 : 767 774.
30. Andersson T, Röhss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001 15 : 1563 1569. (Pubitemid 32912398)
31. Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol 2002 58 : 453 458.
32. Tutuian R, Katz PO, Bochenek W, Castell DO. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther 2002 16 : 829 836.
33. Koop H, Kuly S, Flüg M, et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol 1996 8 : 915 918.
34. Londong W. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994 8 (Suppl 1 39 46.
35. Reill L, Erhardt F, Fischer R, Huber R, Londong W. Dose-response pantoprazole 20, 40 and 80 mg on 24-hour intragastric pH and serum gastrin in man. Gut 1993 34 (suppl. 4 F251.
36. Mönnikes H, Weber S, Tebbe J, et al. Comparison of pantoprazole twice daily with 40 mg once daily on intragastric pH in healthy volunteers. Gastroenterology 1998 114. A232.
37. Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily - a randomized, two-way crossover study. Aliment Pharmacol Ther 2005 21 : 963 967.
38. Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007 8 : 1199 1210.
39. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006 44 : 297 302.
40. Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003 17 : 965 973.